Molnupiravir was developed in response to an urgent unmet need for an orally administered antiviral drug to prevent disease progression in patients with COVID-19. Dr Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) discusses the phase III study assessing the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV2 infection.
The abstract entitled: ‘Phase III Trial of Molnupiravir in Adults with Mild Sars-Cov-2 Infection in India’ (Abstract #101) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- Could you give us a brief overview of the Phase III Molnupiravir clinical trial in India, and the key study findings? (0:34)
- What questions remain unanswered and what will be the next steps for Molnupiravir as a treatment for COVID-19? (6:14)
Disclosures: Nagalingeswaran Kumarasamy has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]